Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Abstract Background The combination of immunotherapy and chemotherapy has demonstrated an enhancement in progression-free survival (PFS) for individuals with advanced and metastatic triple-negative breast cancer (TNBC) when compared to the use of chemotherapy alone. Nevertheless, the extent to which...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shengfa Lin, Bihe Fu, Muhammad Khan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-12-01
coleção:	World Journal of Surgical Oncology
Assuntos:	Breast cancer Immunotherapy Immune checkpoint inhibitors (ICI) Pembrolizumab Atezolizumab Progression-free survival
Acesso em linha:	https://doi.org/10.1186/s12957-024-03424-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!